H H Fernandez
Affiliation: Cleveland Clinic Foundation
- Levodopa-carbidopa intestinal gel in advanced Parkinson's disease open-label study: interim resultsHubert H Fernandez
Center for Neurological Restoration, Cleveland Clinic, 9500 Euclid Ave, U 2, Cleveland, OH 44195, USA
Parkinsonism Relat Disord 19:339-45. 2013..Interim results from this advanced PD cohort demonstrate that LCIG produced meaningful clinical improvements. LCIG was generally well-tolerated; however, device and procedural complications, while generally of mild severity, were common...
- Nonmotor complications of Parkinson diseaseHubert H Fernandez
Movement Disorders Program, Center for Neurological Restoration, Cleveland Clinic, Cleveland, OH 44195, USA
Cleve Clin J Med 79:S14-8. 2012..Thus, a balance must be struck between controlling nonmotor manifestations and motor features of the disease...
- Updates in the medical management of Parkinson diseaseHubert H Fernandez
Center for Neurological Restoration, S31, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA
Cleve Clin J Med 79:28-35. 2012..A cure remains elusive. However, promising interventions and agents are emerging. As an example, people who exercise regularly are less likely to develop Parkinson disease, and if they develop it, they tend to have slower progression...
- Levodopa-carbidopa intestinal gel for treatment of advanced Parkinson's diseaseH H Fernandez
Department of Neurology, Center for Neurological Restoration, Cleveland Clinic, Cleveland, OH 44122, USA
Curr Med Res Opin 27:907-19. 2011..The inability of perorally administered levodopa to provide more physiologic continuous dopaminergic stimulation (CDS) is a leading hypothesis to explain these complications...
- Mood and motor effects of thalamic deep brain stimulation surgery for essential tremorJ Graff-Radford
Department of Neurology, University of Florida Movement Disorders Center, McKnight Brain Institute, Gainesville, FL 32610, USA
Eur J Neurol 17:1040-6. 2010..The aim of this study was to evaluate the effects of unilateral and bilateral ventralis intermedius (Vim) deep brain stimulation (DBS) on mood and motor function...
- Valproate for the treatment of medication-induced impulse-control disorders in three patients with Parkinson's diseaseC W Hicks
Cleveland Clinic Lerner College of Medicine, Cleveland, OH, USA
Parkinsonism Relat Disord 17:379-81. 2011..Based on these encouraging preliminary observations, future controlled clinical trials investigating the efficacy of valproate for ICDs in PD are recommended...
- Perceptual characteristics of Parkinsonian speech: a comparison of the pharmacological effects of levodopa across speech and non-speech motor systemsE K Plowman-Prine
Department of Neurology, University of Florida, Gainesville, FL 32610, USA
NeuroRehabilitation 24:131-44. 2009..No significant differences were obtained between medicated states ('on'/'off') for any of the 35 individual speech dimensions and speech-sign clusters. Global motor function significantly improved following dopaminergic medications...
- Istradefylline as monotherapy for Parkinson disease: results of the 6002-US-051 trialH H Fernandez
Department of Neurology, University of Florida Movement Disorders Center, PO Box 100236, 100 South Newell Dr, L3 100, Gainesville, FL 32610 0236, USA
Parkinsonism Relat Disord 16:16-20. 2010..6002-US-051 was a 12-week, double-blind study evaluating the safety and efficacy of istradefylline, a selective A(2A) adenosine receptor antagonist, as monotherapy in patients with Parkinson's disease (PD)...
- Brain penetration effects of microelectrodes and DBS leads in STN or GPiJ M Mann
Department of Neurology, University of Florida College of Medicine Shands Hospital, Movement Disorders Center, McKnight Brain Institute, Gainesville, Florida 32610, USA
J Neurol Neurosurg Psychiatry 80:794-7. 2009..Secondarily, to evaluate whether the longevity of the MER and lead placement effects were influenced by target location (subthalamic nucleus (STN) or globus pallidus interna (GPi))...
- Is 6 months of neuroleptic withdrawal sufficient to distinguish drug-induced parkinsonism from Parkinson's disease?T T Lim
Center for Neurological Restoration, Cleveland Clinic Foundation, Cleveland, Ohio, USA
Int J Neurosci 123:170-4. 2013..The majority of the literature uses the 6-month timeframe between the neuroleptic withdrawal and resolution of the symptoms of parkinsonism...